| Drug Name: | Tapentadol / Aspadol / Nucynta |
| Tablet Strength: | 50-225 mg |
| Available Packages: | 30 – 360 pills |
| Payment Method: | VISA, MASTERCARD, Wire |
| Shipment: | US2US EU2EU international |
| Buy Now: | Visit Pharmacy |
Pain occurs at nearly every stage of cancer and its treatment, affecting between 50% and 90% of patients. Around 19–39% experience neuropathic pain, while approximately 75% report mixed pain. Accurate diagnosis is essential, as different pain types require distinct therapeutic strategies. Opioids with pure agonist properties are typically prescribed for moderate to severe nociceptive pain, whereas neuropathic pain is managed with adjuvant agents in the first line of therapy.
Tapentadol is a unique centrally acting analgesic that combines two mechanisms of action: mu-opioid receptor (MOR) agonism and norepinephrine reuptake inhibition (NRI). This dual effect makes it particularly effective for mixed pain syndromes and for managing both nociceptive and neuropathic components. Tapentadol is indicated for the management of severe chronic pain in adults when adequate relief cannot be achieved with non-opioid treatments.
Experimental and clinical research has confirmed the efficacy and safety of tapentadol in both acute (somatic and visceral) and chronic pain conditions, including neuropathic pain. While most studies address chronic non-cancer pain, clinical evidence also highlights its role in complex oncologic pain.
In a representative case of pancreatic cancer with chemotherapy-induced neuropathy (managed with gabapentin), persistent visceral pain required a multimodal approach using fentanyl transdermal therapy and oxycodone. Subsequent neurolysis of the celiac plexus was performed, followed by opioid rotation to tapentadol online prolonged release (PR). This strategy reduced baseline visceral and neuropathic pain, as well as the intensity of breakthrough pain episodes, which were managed effectively with rapid-acting transmucosal fentanyl.
Pharmacological Considerations
Effective cancer pain control follows the WHO analgesic ladder, with opioids introduced for moderate to severe pain. The choice of opioid depends on pain mechanism, intensity, patient age, comorbidities, metabolism, psychological status, previous opioid response, and potential history of substance use.
Opioids are classified according to receptor affinity into full agonists, partial agonists, and agonist-antagonists. Pure agonists—such as morphine, oxycodone, or fentanyl—lack a defined maximum dose, while partial agonists (e.g., buprenorphine) exhibit a ceiling effect. Buprenorphine, a partial agonist of μ and δ receptors and antagonist of κ receptors, acts as a pure agonist within therapeutic doses and offers a safety advantage due to its ceiling effect for respiratory depression.
The maximum recommended transdermal buprenorphine dose is 140 mcg/h. Other agonist-antagonists such as butorphanol, nalbuphine, and pentazocine act selectively on different receptors but are rarely used in acute or chronic pain management today.
Opioid receptor affinity is quantified by the Ki value: the smaller the Ki, the stronger the receptor binding.
- Ki > 100 nM: tramadol, codeine, meperidine, propoxyphene, pentazocine
- Ki = 1–100 nM: hydrocodone, oxycodone, diphenoxylate, alfentanil, methadone, nalbuphine, fentanyl, morphine
- Ki < 1 nM: butorphanol, levorphanol, oxymorphone, hydromorphone, buprenorphine, sufentanil
This pharmacological classification underscores the importance of understanding receptor binding strength when tailoring opioid therapy for cancer-related pain.
Cancer pain management commonly relies on opioids that act as pure agonists at opioid receptors—showing strong affinity for μ-receptors and weaker activity at κ and δ sites. Morphine and fentanyl have similar receptor interaction profiles. Methadone binds strongly to μ and δ receptors, while oxycodone shows relatively higher affinity for κ receptors.
Duration of action can be determined pharmacologically (e.g., receptor kinetics with levorphanol or methadone) or by formulation in sustained-release products such as SR morphine, oxycodone, tapentadol PR, transdermal fentanyl, and transdermal buprenorphine.
Typical opioid-related adverse effects—nausea, sedation, constipation, and respiratory depression—result from opioid receptor activation. Less frequent effects, including myoclonus, hallucinations, and disorientation, are not reversed by pure antagonists; management generally requires dose reduction or opioid rotation. Antipsychotics such as quetiapine, haloperidol, olanzapine, or chlorpromazine may be used for hallucinations and myoclonus. Because these symptoms are dose-related, partial or full rotation is often necessary, and metabolic contributors (e.g., hyponatremia, hypercalcemia, CNS metastases) should be ruled out.
Nausea and vomiting occur in about 10–40% of patients early in therapy. Many develop tolerance; some need intermittent antiemetics.
- 60 pills x 50mg
$200.00 $3.33 $31.00 - 90 pills x 50mg
$260.00 $2.89 $86.50 - 120 pills x 50mg
$290.00 $2.42 $172.00 - 180 pills x 50mg
$350.00 $1.94 $343.00
Constipation typically persists throughout opioid therapy because tolerance does not develop. Options include switching to an opioid with a lower constipation risk—for example, converting from a hydrophilic to a more lipophilic agent such as buprenorphine or fentanyl. In refractory cases, a combination of an opioid agonist with a locally acting antagonist (e.g., oxycodone/naloxone) can be effective. The ongoing absence of an opioid with an ideal side-effect profile supports the search for analgesics with different mechanisms that maintain efficacy while reducing adverse events.
How To Buy Tapentadol Online
Tapentadol is a strong step-3 analgesic introduced for chronic pain. An immediate-release form was developed first, followed by a prolonged-release (PR) formulation. In Poland, available PR doses include 50, 100, 150, 200, and 250 mg.
Tapentadol is a centrally acting analgesic with dual mechanisms in a single molecule: mu-opioid receptor (MOR) agonism and norepinephrine reuptake inhibition (NRI). Reported μ-receptor affinity is roughly 50 times weaker than morphine. Affinity for κ, δ, and ORL1 receptors is lower than for MOR, and inhibition of serotonin reuptake is considered negligible.
Preclinical data suggest MOR agonism predominates in acute pain, while NRI contributes synergistically to overall analgesia and appears particularly relevant in chronic pain. In animal models of acute nociception, tapentadol’s effect is strong but approximately 2–3 times weaker than morphine. A commonly used oral morphine–to–tapentadol conversion is 1:3.3.
Metabolism is primarily hepatic via glucuronidation to inactive metabolites (notably glucuronyl-O-tapentadol, ~55%). About 99% of tapentadol and its metabolites are excreted renally and ~1% fecally. Involvement of cytochrome P450 is limited, reducing interaction potential; when present, CYP2C9, CYP2C19, and CYP2D6 are implicated. Tapentadol neither inhibits nor induces major CYP isoenzymes.
In vivo, tapentadol is effective in heat-induced hyperalgesia models and has demonstrated activity in diabetic neuropathy. Its antinociceptive effect is partially reversed by naloxone (reflecting the MOR component) and reduced by yohimbine, an α2-adrenergic blocker, consistent with enhancement of descending inhibitory pathways via norepinephrine.
Safety and tolerability data indicate that, compared with classical full agonists, tapentadol may produce fewer opioid-typical adverse effects. Across comparative studies (morphine–tapentadol, oxycodone–tapentadol, fentanyl–tapentadol), nausea and vomiting occurred less often and were shorter in duration with tapentadol online; adverse events appeared at higher doses, with a much higher symptom-trigger threshold than morphine. Tapentadol also shows a weaker inhibitory effect on intestinal peristalsis than an equianalgesic dose of morphine. Meta-analyses report lower rates of vomiting and constipation versus oxycodone, while dry mouth is more frequent. In opioid-naive cancer patients, studies support both efficacy and tolerability. Given its negligible effect on serotonin reuptake, serotonin-mediated gastrointestinal side effects (e.g., diarrhea from serotonergic excess) are not expected.
Neuropathic Pain in Cancer
According to the International Association for the Study of Pain (IASP), neuropathic pain is defined as pain resulting from injury or disease affecting the somatosensory nervous system. Between 50% and 90% of cancer patients experience pain during the course of their illness, and approximately 19–39% of them develop a neuropathic component. Early recognition of neuropathic symptoms is crucial because treatment strategies differ significantly from those used for nociceptive pain.
Multiple factors can cause neuropathic pain in oncologic patients. These include both tumor-related mechanisms and complications of therapy, such as radiation-induced plexopathy (RIP) and chemotherapy-induced peripheral neuropathy (CIPN). Less frequently, neuropathic pain originates in the abdominal cavity, often going unrecognized in the early stages. Mechanical factors may involve biliary obstruction, intestinal blockage, organ perforation, advanced colorectal carcinoma, or intraperitoneal chemotherapy. Involvement of sympathetic plexuses can also lead to bladder dysfunction or orthostatic hypotension.
In pancreatic cancer, pain may have visceral, somatic, or neuropathic origins. It often results from local inflammation, tissue infiltration, or mechanical compression. Pain signals are transmitted through sympathetic fibers of the visceral plexus (Th12–L2). Patients typically describe stabbing, burning, or pulsating sensations, sometimes mistaken for breakthrough pain. Discomfort tends to worsen at night, disrupt daily activities, and impair basic self-care. The relationship between clinical symptoms and underlying etiology is not always straightforward.
Case Report
A 62-year-old patient with inoperable pancreatic adenocarcinoma (G2) had been receiving palliative chemotherapy for six months. Treatment consisted of 12 cycles of the FOLFIRINOX regimen (fluorouracil, calcium folinate, oxaliplatin, irinotecan). Comorbidities included hypertension, hyperlipidemia, and a history of two myocardial infarctions (2011 and 2014) with subsequent coronary angioplasty. During chemotherapy, grade I neutropenia was observed.
Typical FOLFIRINOX-related toxicities include neutropenia, febrile neutropenia, thrombocytopenia, peripheral neuropathy from platinum compounds, and diarrhea.
The tumor was located in the pancreatic head. The patient reported epigastric pain radiating to the thoracolumbar spine (Th10–12), along with numbness and tingling in the hands and feet (more pronounced distally). These neuropathic symptoms became more intense after the eighth chemotherapy cycle. Pain was mixed—visceral and neuropathic—described as pulsating, squeezing, and radiating to the back. Two distinct neuropathic components were diagnosed: one associated with pancreatic infiltration, and the other related to chemotherapy-induced peripheral neuropathy.
Pain intensity was rated 80–90/100 on the VAS scale, with exacerbations reaching 100.
The clinical diagnosis included visceral abdominal pain due to pancreatic cancer and peripheral neuropathy affecting the extremities. The patient was referred for interventional pain management, including potential celiac plexus neurolysis.
At admission, ECOG performance status was 2. Laboratory results indicated normal liver and kidney function. Pre-cachexia symptoms were present; nutritional risk score (NRS 2002) was 2. Surgery was postponed pending cardiac assessment because of a borderline ejection fraction (EF ≈ 45%), which increases the risk of hypotension after abdominal vasodilation.
Analgesic Management
The patient’s prior medications included oxycodone 60 mg twice daily, transdermal fentanyl 150 µg/h every 72 h, and immediate-release morphine 20 mg as needed. Additional drugs were low-molecular-weight heparin, spironolactone, furosemide, metoprolol, pancreatin, alprazolam, and ketoprofen preparations.
Abdominal CT confirmed advanced local disease: a solid-cystic mass in the pancreatic head (83 × 87 × 70 mm) invading the celiac trunk and superior mesenteric artery, with peripancreatic lymphadenopathy. No hepatic or osseous metastases were found.
Oxycodone dosage was gradually increased to 200 mg/day (below calculated morphine-equivalent levels). Fentanyl transdermal therapy was tapered from 150 µg/h to 100 µg/h, then to 50 µg/h over three days. Slow opioid rotation improved tolerability. Rescue therapy consisted of morphine IR 20 mg orally as needed. Lactulose (3 × 20 mL) was prescribed to prevent constipation. Gabapentin was introduced (100 mg three times daily, titrated to 300 mg t.i.d.) for chemotherapy-induced neuropathy.
Adequate pain relief was achieved initially, but after four days the patient developed increasing constipation, with hard stool every 3–4 days, bloating, nausea, and anorexia. Because tolerance to opioid-induced constipation does not develop, switching to an opioid with a lower risk profile was recommended. Part of the oxycodone dose (200 mg/day) was replaced with a fixed oxycodone–naloxone combination (60 mg oxycodone / naloxone + 140 mg oxycodone daily). For breakthrough pain, transmucosal fentanyl 400 µg (after titration) was prescribed up to four times daily.
Insufficient pain relief despite relatively high opioid doses suggested tolerance to the existing regimen. Conversion to another opioid was indicated due to limited efficacy, growing side effects, and an unfavorable balance between analgesia and tolerability.
Opioid Tolerance and Treatment Adjustment
Opioid tolerance must be distinguished from the intrinsic resistance of certain pain types—particularly neuropathic pain—to opioid therapy. When tolerance develops or when the first opioid is used at high doses, rotation to another opioid should begin at 25–50% of the calculated equianalgesic dose. Conversion tables provide only general guidance and should be applied with caution.
Because of unsatisfactory pain control and progressive opioid-induced constipation, celiac plexus neurolysis was performed after confirming adequate cardiac function (EF 49%). The procedure produced a clear analgesic effect. In the following days, the oxycodone dose was gradually reduced every three days while maintaining gabapentin at 300 mg three times daily. Transmucosal fentanyl (200 µg) was continued for breakthrough pain. The patient’s baseline pain decreased to 50 mm on the VAS scale.
Recurrent nausea and vomiting prompted imaging, which showed partial intestinal obstruction. Conservative therapy was implemented with intravenous metoclopramide, antispasmodics, and dexamethasone. Given the previous high fentanyl transdermal dose (150 µg/h) and limited response, reintroduction of the patch was not considered effective. Subcutaneous administration was avoided because of peripheral edema and anticoagulant therapy, which increased hematoma risk and impaired absorption.
Over the next four days, intravenous morphine was administered via a patient-controlled analgesia (PCA) pump. The calculated conversion was oxycodone 200 mg = morphine 300 mg (1:1.5 ratio). One-third of the oral dose (100 mg) was given intravenously over 24 hours (4.1 mg/h continuous infusion), with an additional 1 mg PCA bolus and a 15-minute lockout.
After controlling gastrointestinal symptoms, morphine was replaced with oral tapentadol prolonged-release (PR). The decision was based on the mixed nature of the pain—both visceral and neuropathic—and on the favorable gastrointestinal tolerability of tapentadol compared with oxycodone or morphine. Tapentadol PR 200 mg twice daily (slightly below the equianalgesic dose) was prescribed, along with transmucosal fentanyl 200 µg as rescue medication. Following celiac plexus neurolysis and opioid rotation, baseline pain stabilized at approximately 40 mm on the VAS scale.
Final recommendations included:
- • Tapentadol PR 200 mg b.i.d.
- • Transmucosal fentanyl 200 µg up to 4 times daily for breakthrough pain
- • Gabapentin 300 mg t.i.d., with gradual tapering during withdrawal
It should be noted that after effective control of visceral pain, neuropathic symptoms may subjectively appear stronger as they become more prominent.
Discussion
Neuropathic pain is characterized by abnormal sensory processing within the nervous system, leading to spontaneous pain, allodynia (pain from normally non-painful stimuli), and hyperalgesia (heightened pain response). Central sensitization occurs at both spinal and supraspinal levels. Descending inhibitory pathways originating from the midbrain and medulla modulate pain transmission via serotonin and norepinephrine. Activation of α₂-adrenergic receptors by norepinephrine suppresses ascending pain signals.
The serotonergic pathway can either inhibit or facilitate nociceptive transmission depending on receptor subtype. Following nerve injury, descending facilitation may increase, explaining the limited efficacy of selective serotonin reuptake inhibitors (SSRIs) in chronic neuropathic pain—they simultaneously activate both inhibitory and excitatory 5-HT receptors.
Buy Tapentadol, which lacks serotonergic activity, acts through dual mechanisms: enhancing descending noradrenergic inhibition and activating μ-opioid receptors to suppress ascending pain pathways. This pharmacological profile makes it a valuable option for neuropathic pain syndromes. Tapentadol binds weakly to plasma proteins (~20%), minimizing drug–protein displacement interactions, and its inactive metabolites further reduce the risk of drug–drug interactions. Minimal CYP450 involvement lowers the potential for metabolic interference.
Celiac plexus neurolysis is primarily used for upper-abdominal visceral pain caused by pancreatic, gastric, or hepatic malignancies or chronic pancreatitis. The procedure yields the best results when the tumor involves the pancreatic tail. Most patients experience a marked reduction in baseline pain and lower opioid requirements, along with fewer side effects and improved quality of life. The analgesic effect typically lasts 2–3 months, while breakthrough pain may persist at a lower intensity and requires separate management.
For patients with nausea, vomiting, or dysphagia, transdermal fentanyl or buprenorphine offers a suitable alternative to subcutaneous or intravenous opioids.
Chemotherapy-induced peripheral neuropathy (CIPN), particularly from oxaliplatin, remains a frequent and challenging adverse effect. Current management follows general neuropathic pain guidelines, with gabapentin, pregabalin, duloxetine, baclofen gels, and amitriptyline considered first-line options. Tapentadol’s dual mechanism and favorable safety profile support its consideration in CIPN management, though further research is needed to establish its role as monotherapy or in combination regimens.
Summary
Approximately 80% of patients with advanced pancreatic cancer experience severe or very severe pain, often of mixed origin. Undiagnosed neuropathic components contribute to inadequate analgesia and inappropriate opioid selection. Effective pain management remains a key objective of palliative care. Achieving adequate control requires optimal dosing, appropriate opioid choice, and management of side effects.
When analgesia is insufficient, opioid rotation or dose adjustment, addition of adjuvants, and individualized rescue strategies are recommended. Changing the route of administration (oral → parenteral → transdermal) may improve efficacy and tolerance. If pharmacological measures fail, interventional pain techniques should be considered.
Celiac plexus neurolysis, while not completely eliminating pain, significantly reduces baseline discomfort, lowers opioid consumption, and improves quality of life. Most cancer patients ultimately present with mixed pain (≈ 74%), requiring therapies that address both nociceptive and neuropathic mechanisms.
Tapentadol, combining μ-opioid receptor agonism and norepinephrine reuptake inhibition, provides effective analgesia for mixed and neuropathic pain with a favorable tolerability profile. Studies show reduced gastrointestinal adverse effects compared with morphine, oxycodone, and fentanyl. Its non-serotonergic action minimizes the risk of serotonin syndrome and related gastrointestinal symptoms.
Long-term data indicate that tapentadol is associated with slower tolerance development and improved adherence through its opioid-sparing effect and balanced dual mechanism. Further clinical trials are warranted to confirm its role in treating mixed and neuropathic cancer pain, including CIPN.
